Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2020
Biotech
UniQure/CSL hem B gene therapy curbs bleeding in phase 3
CSL and uniQure's hemophilia B gene therapy curbed bleeding episodes by 91% and nearly eliminated the need for infusions of clotting factors.
Amirah Al Idrus
Dec 8, 2020 10:10am
Novartis' asciminib tops Pfizer's Bosulif in head-to-head trial
Dec 8, 2020 10:00am
CRISPR-edited CAR-Ts show enhanced activity in leukemia models
Dec 7, 2020 8:45am
Allogene CAR-T posts 60% response rate in competitive BCMA field
Dec 7, 2020 8:03am
Regeneron's bispecific banishes 2 kinds of lymphoma
Dec 6, 2020 3:00pm
ASH: J&J’s subcut BCMA bispecific hits 73% response rate
Dec 5, 2020 3:00pm
